Literature DB >> 1510423

Pharmacologic modulation of interleukin-1 expression by amphotericin B-stimulated human mononuclear cells.

J D Cleary1, S W Chapman, R L Nolan.   

Abstract

Fever and chills occur frequently with amphotericin B (AB) administration, but the mechanism that causes these reactions has not been definitively established. A variety of proinflammatory cytokines, including interleukin-1 (IL-1) and tumor necrosis factor, have been shown to be important mediators of fever. In order to clarify the cellular and biochemical responses associated with AB-induced fever, the experiments described sought to (i) establish whether human mononuclear cells exposed to AB in vitro expressed IL-1 beta, (ii) evaluate whether clinically used premedications for fever prophylaxis in AB-treated patients were effective in down-regulating IL-1 beta expression in vitro, (iii) evaluate whether methylxanthine agents with immunomodulatory actions effected in vitro IL-1 beta expression, and (iv) define the dose and time dependency of the modulating effects. Peripheral blood mononuclear cells were isolated by density centrifugation and resuspended to 10(6) cells per ml in culture wells of Linbro plates. When cocultured for 2 h with human mononuclear cells, both Escherichia coli lipopolysaccharide and AB stimulated IL-1 beta expression in a dose-related fashion. AB-induced IL-1 beta expression was suppressed by hydrocortisone (HC), pentoxifylline, and an investigational theobromine, A81-3138, in a linear, dose-related manner. In contrast, indomethacin, meperidine, and diphenhydramine had no effect on IL-1 beta expression. Our in vitro data indicate that serum HC concentrations of greater than 1 to 2 micrograms/ml may be sufficient to modulate IL-1 beta expression. Pentoxifylline and A81-3138 may also be effective in modulating IL-1 beta expression by mononuclear cells at concentrations achievable in serum. These new agents may prove to be effective alternatives to HC or may be added with HC to suppress febrile reactions secondary to AB administration. Clinical studies with pentoxifylline as a premedication for AB seem warranted.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1510423      PMCID: PMC188802          DOI: 10.1128/AAC.36.5.977

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Reducing amphotericin B reactions. A double-blind study.

Authors:  B S TYNES; J P UTZ; J E BENNETT; D W ALLING
Journal:  Am Rev Respir Dis       Date:  1963-02

2.  Effect of diclofenac on prostaglandin E and hyaluronic acid production by human synovial fibroblasts stimulated with interleukin-1.

Authors:  F A Meyer; I Yaron; V Mashiah; M Yaron
Journal:  Br J Clin Pharmacol       Date:  1989-08       Impact factor: 4.335

3.  Interleukin-1 induces tumor necrosis factor (TNF) in human peripheral blood mononuclear cells in vitro and a circulating TNF-like activity in rabbits.

Authors:  T Ikejima; S Okusawa; P Ghezzi; J W van der Meer; C A Dinarello
Journal:  J Infect Dis       Date:  1990-07       Impact factor: 5.226

4.  Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline.

Authors:  R M Strieter; D G Remick; P A Ward; R N Spengler; J P Lynch; J Larrick; S L Kunkel
Journal:  Biochem Biophys Res Commun       Date:  1988-09-30       Impact factor: 3.575

5.  Measurement of immunoreactive interleukin-1 beta from human mononuclear cells: optimization of recovery, intrasubject consistency, and comparison with interleukin-1 alpha and tumor necrosis factor.

Authors:  S Endres; R Ghorbani; G Lonnemann; J W van der Meer; C A Dinarello
Journal:  Clin Immunol Immunopathol       Date:  1988-12

6.  Effects of corticosteroid therapy on human monocyte function.

Authors:  J J Rinehart; A L Sagone; S P Balcerzak; G A Ackerman; A F LoBuglio
Journal:  N Engl J Med       Date:  1975-01-30       Impact factor: 91.245

7.  Effects of prostaglandins and cAMP levels on monocyte IL-1 production.

Authors:  S Kassis; J C Lee; N Hanna
Journal:  Agents Actions       Date:  1989-06

Review 8.  New concepts on the pathogenesis of fever.

Authors:  C A Dinarello; J G Cannon; S M Wolff
Journal:  Rev Infect Dis       Date:  1988 Jan-Feb

9.  Macrophage inflammatory protein-1: a prostaglandin-independent endogenous pyrogen.

Authors:  G Davatelis; S D Wolpe; B Sherry; J M Dayer; R Chicheportiche; A Cerami
Journal:  Science       Date:  1989-02-24       Impact factor: 47.728

10.  Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway.

Authors:  J Han; P Thompson; B Beutler
Journal:  J Exp Med       Date:  1990-07-01       Impact factor: 14.307

View more
  15 in total

Review 1.  Adverse drug reactions to systemic antifungals. Prevention and management.

Authors:  J R Perfect; M H Lindsay; R H Drew
Journal:  Drug Saf       Date:  1992 Sep-Oct       Impact factor: 5.606

Review 2.  Key issues concerning fungistatic versus fungicidal drugs.

Authors:  J R Graybill; D S Burgess; T C Hardin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-01       Impact factor: 3.267

3.  Reduction of no synthase expression and tumor necrosis factor alpha production in macrophages by amphotericin B lipid carriers.

Authors:  M Larabi; P Legrand; M Appel; S Gil; M Lepoivre; J Devissaguet; F Puisieux; G Barratt
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

4.  Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial.

Authors:  U Eriksson; B Seifert; A Schaffner
Journal:  BMJ       Date:  2001-03-10

5.  Secretion of proinflammatory cytokines and chemokines during amphotericin B exposure is mediated by coactivation of toll-like receptors 1 and 2.

Authors:  Raymund R Razonable; Martin Henault; Linda N Lee; Carmen Laethem; Paul A Johnston; Harold L Watson; Carlos V Paya
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

6.  Topical treatment with nanoliposomal Amphotericin B reduces early lesion growth but fails to induce cure in an experimental model of cutaneous leishmaniasis caused by Leishmania mexicana.

Authors:  Sanjay Varikuti; Steve Oghumu; Noushin Saljoughian; Marissa S Pioso; Bren E Sedmak; Ali Khamesipour; Abhay R Satoskar
Journal:  Acta Trop       Date:  2017-06-09       Impact factor: 3.112

Review 7.  In search of the holy grail of antifungal therapy.

Authors:  Stanley W Chapman; Donna C Sullivan; John D Cleary
Journal:  Trans Am Clin Climatol Assoc       Date:  2008

8.  Polymyxin B stimulates production of complement components and cytokines in human monocytes.

Authors:  A K Høgåsen; T G Abrahamsen
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

9.  Tumor necrosis factor alpha has a protective role in a murine model of systemic candidiasis.

Authors:  A Louie; A L Baltch; R P Smith; M A Franke; W J Ritz; J K Singh; M A Gordon
Journal:  Infect Immun       Date:  1994-07       Impact factor: 3.441

10.  It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug.

Authors:  Ana C Mesa-Arango; Liliana Scorzoni; Oscar Zaragoza
Journal:  Front Microbiol       Date:  2012-08-08       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.